Results 101 to 110 of about 443,809 (299)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Haematologica, 2019
There are no validated molecular biomarkers to identify newly-diagnosed individuals with chronic-phase chronic myeloid leukemia likely to respond poorly to imatinib and who might benefit from first-line treatment with a more potent second-generation ...
Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, Gareth Gerrard, Edward Curry, Richard Szydlo, Mary Alikian, Hui En Foong, Zacharoula Nikolakopoulou, Sandra Loaiza, Jamshid S. Khorashad, Dragana Milojkovic, Danilo Perrotti, Robert Peter Gale, Letizia Foroni, Jane F. Apperley   +15 more
doaj   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Haematologica, 2013
There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative ...
Antonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Luigiana Luciano, Antonella Gozzini, Mario Annunziata, Bruno Martino, Fabio Stagno, Francesco Cavazzini, Mario Tiribelli, Giuseppe Visani, Patrizia Pregno, Pellegrino Musto, Carmen Fava, Nicola Sgherza, Francesco Albano, Gianantonio Rosti, Giuliana Alimena, Giorgina Specchia   +19 more
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

JAK inhibitors: a new choice for diabetes mellitus?

Diabetology & Metabolic Syndrome
Altered tyrosine kinase signaling is associated with a variety of diseases. Tyrosine kinases can be classified into two groups: receptor type and nonreceptor type. Nonreceptor-type tyrosine kinases are subdivided into Janus kinases (JAKs), focal adhesion
Mengjun Zhou, Qi Shen, Bo Li
doaj   +1 more source

NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. [PDF]

, 2018
Notch dysregulation has been implicated in numerous tumors, including triple-negative breast cancer (TNBC), which is the breast cancer subtype with the worst clinical outcome.
Bellavia, Diana, Besharat, ZEIN MERSINI, Capalbo, Carlo, Checquolo, Saula, D'Amati, Giulia, Del Gaudio, Francesca, Diluvio, Giulia, Franciosa, Giulia, Giuli, MARIA VALERIA, Giuliani, Eugenia, Maroder, Marella, Palermo, Rocco, Pignataro, MARIA GEMMA, Talora, Claudio, Vacca, Alessandra   +14 more
core   +2 more sources

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Progression in treatment of advanced gastrointestinal stromal tumors [PDF]

Waike lilun yu shijian
Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinase are key drivers of most gastrointestinal stromal tumor (GIST). The continuous development of tyrosine kinase inhibitors, such as imatinib, sunitinib, anlotinib, regorafenib, ripretinib ...
TANG Haixiao, ZHANG Yun, HAN Gang, GONG Hangjun
doaj   +1 more source

Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? [PDF]

, 2011
No abstract ...
Amaravadi, Arunima Mukhopadhyay, Bellodi, Belloni, Boya, Druker, Furst, Gordon, Gozuacik, Gudmundur V Helgason, Jiang, Kalia, Kim, Maria Karvela, Munster, Naka, Ozvegy-Laczka, Savarino, Sharma, Tessa L Holyoake, Zaidi   +20 more
core   +1 more source

Establishment of in vitro Src tyrosine kinase inhibitors screening model

浙江大学学报. 农业与生命科学版, 2007
A model system for rapid screening of Src tyrosine kinase inhibitors was established in vitro, and it is the foundation of screening tyrosine kinase activity inhibitors.
WANG Chen-hui, SHI Ying, GONG Xing-guo
doaj   +1 more source